TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27647052

Group type: EXPERIMENTAL
Intervention: Trauma-focused cognitive behavioral therapy (TF-CBT)
Number of subjects: 257
Study: 25194223

Group type: EXPERIMENTAL
Intervention: BBTI-MV (brief behavioral treatment of insomnia)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Information only control (IC)
Number of subjects: 40
Study: 23720367

Group type: EXPERIMENTAL
Intervention: Multivitamin supplementation (vitamins B complex, C, and E)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Vaccination at 10 to 11 months
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Maternal CD4 T-cell count <200 cells/μl
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Stunted infants
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Lower infant height-for-age z-scores
Number of subjects: 201
Study: 20954671

Group type: EXPERIMENTAL
Intervention: Mini-midvastus approach (group A)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Mini-medial parapatellar approach (group B)
Number of subjects: 134
Study: 18472087

Group type: EXPERIMENTAL
Intervention: Demineralisation solution with 1 ppm fluoride for five days
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Demineralisation solution with 5 ppm fluoride for five days
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no demineralisation solution)
Number of subjects: 45
Study: 19299808

Group type: COMPARATOR
Intervention: EDA group (15 patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: EDA-NE group (5 patients)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (10 patients)
Number of subjects: 20
Study: 15177597

Group type: EXPERIMENTAL
Intervention: Nonpenetrating deep sclerectomy with T‐flux implant
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Viscocanalostomy
Number of subjects: 34

Group type: COMPARATOR
Intervention: Trabeculectomy
Number of subjects: 34
Study: 11561335

Group type: EXPERIMENTAL
Intervention: Decision-making aid (manual and audiocassette describing a six-step approach to making a decision about HRT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Information document from the Society of Obstetricians and Gynaecologists of Canada (SOGC)
Number of subjects: 0
Study: 9621483

Group type: EXPERIMENTAL
Intervention: EPI + DEX (1,000 mg/m2 i.v.)
Number of subjects: 95

Group type: COMPARATOR
Intervention: EPI (160 mg/m2 i.v. every 3 weeks)
Number of subjects: 95
Study: 7842365

Group type: EXPERIMENTAL
Intervention: KW 4679 (2.5, 5, or 10 mg b.i.d.)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Terfenadine (60 mg b.i.d.)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: KW 4679 (all doses)
Number of subjects: 15
Study: 3279968

Group type: COMPARATOR
Intervention: Acipimox 750 mg/day for 60 days
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Acipimox 750 mg/day for first 6 months, then 1200 mg/day for last 3 months
Number of subjects: 17
Study: 30673687

Group type: EXPERIMENTAL
Intervention: Individualized exercise prescription
Number of subjects: 39

Group type: COMPARATOR
Intervention: Standardized exercise prescription
Number of subjects: 39
Study: 26775560

Group type: EXPERIMENTAL
Intervention: LNS-LQ/Cash
Number of subjects: 2586

Group type: COMPARATOR
Intervention: LNS-MQ/Cash
Number of subjects: 2586
Study: 25738348

Group type: EXPERIMENTAL
Intervention: 3-month loading group (group 1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 6-month loading group (group 2)
Number of subjects: 36
Study: 24921223

Group type: EXPERIMENTAL
Intervention: FlexTouch 100 (FT100)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: FlexTouch 200 (FT200)
Number of subjects: 128

Group type: COMPARATOR
Intervention: SoloSTAR
Number of subjects: 128
Study: 21178179

Group type: EXPERIMENTAL
Intervention: Late RES ewes (60% of NRC recommendations)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ewes fed ASe (3.05 μg/kg of BW)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Combination of Se treatment and late gestation nutritional level
Number of subjects: 64
Study: 19500346

Group type: EXPERIMENTAL
Intervention: Stepped care program consisting of Watchful waiting, Guided self-help, Problem Solving Treatment, Medication and/or specialized mental health care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 0
Study: 17548729

Group type: EXPERIMENTAL
Intervention: NT-proBNP testing
Number of subjects: 500
Study: 14765861

Group type: EXPERIMENTAL
Intervention: Oral ferrous sulphate for six weeks
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo for six weeks
Number of subjects: 72
Study: 11739066

Group type: EXPERIMENTAL
Intervention: Carbamazepine (400 mg/day)
Number of subjects: 21
Study: 10436966

Group type: EXPERIMENTAL
Intervention: Enalapril (E)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Metoprolol (M)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Nifedipine (N)
Number of subjects: 90
Study: 7935703

Group type: EXPERIMENTAL
Intervention: Polymethyl methacrylate membrane
Number of subjects: 72

Group type: COMPARATOR
Intervention: Cuprophane membrane
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Polymethyl methacrylate membrane (nonoliguric acute renal failure)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Cuprophane membrane (nonoliguric acute renal failure)
Number of subjects: 72
Study: 3284549

Group type: EXPERIMENTAL
Intervention: Defibrinogenation therapy
Number of subjects: 162

Group type: COMPARATOR
Intervention: Steroid therapy
Number of subjects: 162
Study: 30463524

Group type: EXPERIMENTAL
Intervention: Mobile phone reminders
Number of subjects: 662

Group type: COMPARATOR
Intervention: Physical contact tracing reminders
Number of subjects: 662
Study: 26658775

Group type: EXPERIMENTAL
Intervention: Real-time feedback on safety checklist compliance and efficiency metrics via display boards and text messages
Number of subjects: 1886

Group type: COMPARATOR
Intervention: No feedback on safety checklist compliance and efficiency metrics
Number of subjects: 1886
Study: 25171799

Group type: EXPERIMENTAL
Intervention: McGrath MAC
Number of subjects: 39
Study: 22050040

Group type: EXPERIMENTAL
Intervention: Brimonidine tartrate (BT) 0.5% once daily
Number of subjects: 391

Group type: COMPARATOR
Intervention: Brimonidine tartrate (BT) 0.18% once daily
Number of subjects: 391

Group type: COMPARATOR
Intervention: Vehicle once daily
Number of subjects: 391

Group type: COMPARATOR
Intervention: Brimonidine tartrate (BT) 0.18% twice daily
Number of subjects: 391

Group type: COMPARATOR
Intervention: Vehicle twice daily
Number of subjects: 391

Group type: COMPARATOR
Intervention: Brimonidine tartrate (BT) 0.07%
Number of subjects: 391

Group type: COMPARATOR
Intervention: Brimonidine tartrate (BT) 0.18%
Number of subjects: 391

Group type: COMPARATOR
Intervention: Single application of BT 0.5%
Number of subjects: 391
Study: 20738023

Group type: EXPERIMENTAL
Intervention: Passive tilting using 'Lojer 1445YH'
Number of subjects: 36

Group type: COMPARATOR
Intervention: Functional bed position change (Control)
Number of subjects: 36
Study: 18279480

Group type: EXPERIMENTAL
Intervention: Antibacterial agents RCTs
Number of subjects: 70
Study: 16321130

Group type: EXPERIMENTAL
Intervention: ACL-deficient knees
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Variation of tibiofemoral contact pattern
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Time since injury
Number of subjects: 23
Study: 11912359

Group type: EXPERIMENTAL
Intervention: brimonidine-Purite 0.15%
Number of subjects: 1147

Group type: EXPERIMENTAL
Intervention: brimonidine-Purite 0.2%
Number of subjects: 1147

Group type: COMPARATOR
Intervention: brimonidine 0.2%
Number of subjects: 1147
Study: 10220833

Group type: EXPERIMENTAL
Intervention: No medication or nonsteroidal antirheumatic drugs
Number of subjects: 20

Group type: COMPARATOR
Intervention: Glucocorticoids (in group II)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy individuals (control group III)
Number of subjects: 20
Study: 8935108

Group type: COMPARATOR
Intervention: Acid etching of enamel alone for fragment bonding (n = 146)
Number of subjects: 334

Group type: EXPERIMENTAL
Intervention: Combination of enamel etching and dentinal bonding (n = 188)
Number of subjects: 334
Study: 2696710

Group type: EXPERIMENTAL
Intervention: Diclofenac eyedrops
Number of subjects: 179

Group type: COMPARATOR
Intervention: Placebo eyedrops
Number of subjects: 179
Study: 12675

Group type: EXPERIMENTAL
Intervention: Injectable combination of local anaesthetic (Xylestesin) and beta-receptor-blocker (Betadrenol)
Number of subjects: 30
Study: 29237134

Group type: EXPERIMENTAL
Intervention: Investigational liquid nutritional formula (1g gamma-linolenic acid, 750μg iodine, 70μg selenium)
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control formula (without GLA, iodine, and selenium)
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Investigational liquid nutritional formula
Number of subjects: 188

Group type: COMPARATOR
Intervention: Control formula
Number of subjects: 188
Study: 27732968

Group type: EXPERIMENTAL
Intervention: Paclitaxel (standard dose and schedule)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: SBF2 variants
Number of subjects: 213
Study: 24609851

Group type: EXPERIMENTAL
Intervention: Community-engaged approaches including colearning opportunities, participatory procedures for community-academic involvement, and community and clinical capacity building.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 22816732

Group type: EXPERIMENTAL
Intervention: High-dose statin therapy
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control (normocholesterolemic subjects)
Number of subjects: 91
Study: 21197853

Group type: EXPERIMENTAL
Intervention: Actual microgravity (AM)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Simulated microgravity (SM)
Number of subjects: 5
Study: 18956981

Group type: EXPERIMENTAL
Intervention: Higher religiosity scores
Number of subjects: 0
Study: 16184071

Group type: EXPERIMENTAL
Intervention: Chromium picolinate (CrPic) 600 mug/day
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Chromium picolinate (CrPic) in patients with high carbohydrate craving
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo in patients with high carbohydrate craving
Number of subjects: 113
Study: 12519653

Group type: EXPERIMENTAL
Intervention: 20 mg arecoline
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 5 mg arecoline
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: 10 mg arecoline
Number of subjects: 23

Group type: COMPARATOR
Intervention: Areca nut (various doses)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Areca nut (postprandial)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Areca nut
Number of subjects: 23
Study: 11769869

Group type: EXPERIMENTAL
Intervention: Greater occipital nerve block (GON)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C2/C3 nerve block
Number of subjects: 0
Study: 9086386

Group type: EXPERIMENTAL
Intervention: Electrical stimulation (ES + TED)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sequential compression device (SCD + TED)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 8460756

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg (group 1)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Omeprazole 80 mg (group 2)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg + Metoclopramide 10 mg (group 3)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Omeprazole 80 mg + Metoclopramide 10 mg (group 4)
Number of subjects: 94
Study: 3956895

Group type: EXPERIMENTAL
Intervention: 20 min daily bicycle exercise
Number of subjects: 13

Group type: COMPARATOR
Intervention: Non-exercising controls
Number of subjects: 13
Study: 30859987

Group type: EXPERIMENTAL
Intervention: Valbenazine 40mg
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Valbenazine 80mg
Number of subjects: 95
Study: 30202085

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 2 mg/kg every 3 weeks (Q3W) or 10 mg/kg Q2W or Q3W
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Pembrolizumab in ipilimumab-naive patients
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Pembrolizumab in ipilimumab-treated patients
Number of subjects: 84
Study: 27812149

Group type: COMPARATOR
Intervention: Acarbose
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 60
Study: 25095772

Group type: EXPERIMENTAL
Intervention: Vitamin C (2 grams taken one hour before exposure)
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo (taken one hour before exposure)
Number of subjects: 63
Study: 23194486

Group type: EXPERIMENTAL
Intervention: Continuous intravenous diuretics
Number of subjects: 308

Group type: COMPARATOR
Intervention: Bolus intravenous diuretics
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: High initial intravenous diuretic dose
Number of subjects: 308

Group type: COMPARATOR
Intervention: Low initial intravenous diuretic dose
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: High outpatient diuretic doses
Number of subjects: 308

Group type: COMPARATOR
Intervention: Low outpatient diuretic doses
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Mode of therapy (bolus vs continuous)
Number of subjects: 308
Study: 20413082

Group type: EXPERIMENTAL
Intervention: Activ-O-Meter (internet-based computer-tailored physical activity intervention)
Number of subjects: 675

Group type: COMPARATOR
Intervention: Generic standard advice (control)
Number of subjects: 675
Study: 18640939

Group type: EXPERIMENTAL
Intervention: C8092A C/A or A/A genotypes
Number of subjects: 233

Group type: COMPARATOR
Intervention: C/C genotype
Number of subjects: 233

Group type: EXPERIMENTAL
Intervention: Codon 118 polymorphism
Number of subjects: 233
Study: 15845553

Group type: EXPERIMENTAL
Intervention: Awareness of noise hazard (93%)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Knowledge of prevention methods (92%)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Possession of hearing protectors (27%)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Usage of hearing protectors (28%)
Number of subjects: 116
Study: 11171733

Group type: EXPERIMENTAL
Intervention: Filgrastim (300 microg) administered IV daily for up to 5 days
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo administered IV daily for up to 5 days
Number of subjects: 18
Study: 9665023

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 5% solution of glucose (Control)
Number of subjects: 30
Study: 8144338

Group type: EXPERIMENTAL
Intervention: Quiet conditions for group A readers (accustomed to quiet environment)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Noisy conditions for group A readers (accustomed to quiet environment)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Quiet conditions for group B readers (accustomed to noisy environments)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Noisy conditions for group B readers (accustomed to noisy environments)
Number of subjects: 120
Study: 3276282

Group type: EXPERIMENTAL
Intervention: Phenelzine sulfate
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Imipramine hydrochloride
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119
Study: 1581424

Group type: EXPERIMENTAL
Intervention: MK-212
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 66167

Group type: EXPERIMENTAL
Intervention: Immune serum globulin preoperatively
Number of subjects: 44

Group type: COMPARATOR
Intervention: Albumin placebo
Number of subjects: 44
Study: 31994271

Group type: EXPERIMENTAL
Intervention: TPF induction chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TPF chemotherapy and PI3K-AKT-mTOR inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: High stathmin expression
Number of subjects: 0
Study: 30660818

Group type: EXPERIMENTAL
Intervention: Whipple accelerated recovery pathway (WARP)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Control (traditional 7-day pathway)
Number of subjects: 76
Study: 26456628

Group type: EXPERIMENTAL
Intervention: Blinded BFR (n = 16)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Nonblinded BFR (n = 13)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo (n = 14)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Blinded BFR vs Nonblinded BFR
Number of subjects: 43
Study: 25784079

Group type: EXPERIMENTAL
Intervention: Daily meditation for six weeks (treatment group)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 27
Study: 24081232

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (ILI)
Number of subjects: 3899

Group type: COMPARATOR
Intervention: Control group (diabetes support and education)
Number of subjects: 3899
Study: 21619828

Group type: EXPERIMENTAL
Intervention: 20 mg simvastatin, taken in evening for 4 months
Number of subjects: 96

Group type: COMPARATOR
Intervention: 2.5 mg warfarin, once a day for 4 months
Number of subjects: 96
Study: 19821135

Group type: EXPERIMENTAL
Intervention: Outpatient rehabilitation
Number of subjects: 163

Group type: COMPARATOR
Intervention: Inpatient rehabilitation
Number of subjects: 163
Study: 16753449

Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b (5 x 10(6) U) biweekly for 12 weeks
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo (saline 10 ml) biweekly for 12 weeks
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Interferon alpha‐2b
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study: 15912723

Group type: EXPERIMENTAL
Intervention: Familiar event
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfamiliar event
Number of subjects: 0
Study: 11487170

Group type: EXPERIMENTAL
Intervention: Erbium, chromium:YSGG laser irradiation with water spray cooling
Number of subjects: 60

Group type: COMPARATOR
Intervention: Erbium, chromium:YSGG laser irradiation without cooling
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Erbium, chromium:YSGG laser irradiation with cooling
Number of subjects: 60
Study: 9663366

Group type: EXPERIMENTAL
Intervention: Bupropion SR 150 mg/d (150 mg QD)
Number of subjects: 362

Group type: EXPERIMENTAL
Intervention: Bupropion SR 300 mg/d (150 mg BID)
Number of subjects: 362

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study: 7829013

Group type: EXPERIMENTAL
Intervention: Ispaghula 18 g/day
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 3046791

Group type: EXPERIMENTAL
Intervention: darodipine 50 mg twice a day
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: darodipine 100 mg twice a day
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: darodipine 150 mg twice a day
Number of subjects: 43

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 43
Study: 29611518

Group type: EXPERIMENTAL
Intervention: 3 months of oxaliplatin-containing chemotherapy
Number of subjects: 6088

Group type: COMPARATOR
Intervention: 6 months of oxaliplatin-containing chemotherapy
Number of subjects: 6088
Study: 27629438

Group type: EXPERIMENTAL
Intervention: CBT-based Anger Management Training (12-week program)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 85
Study: 25843292

Group type: EXPERIMENTAL
Intervention: Ag-DC-CIK immunotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CIK treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ag-DC-CIK treatment
Number of subjects: 0
Study: 23627672

Group type: EXPERIMENTAL
Intervention: Polylactide-based temporary skin substitute
Number of subjects: 0

Group type: COMPARATOR
Intervention: Autologous skin grafts
Number of subjects: 0
Study: 21865087

Group type: EXPERIMENTAL
Intervention: HPV vaccine (Cervarix, GlaxoSmithKline)
Number of subjects: 4210

Group type: COMPARATOR
Intervention: Control hepatitis A vaccine (modified preparation of Havrix, GlaxoSmithKline)
Number of subjects: 4210
Study: 19968681

Group type: EXPERIMENTAL
Intervention: Dobutamine
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Flow-mediated dilatation (FMD)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Dobutamine alone or associated with placebo or L-arginine
Number of subjects: 27

Group type: COMPARATOR
Intervention: L-arginine infusion
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 16713455

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) plus narrowband UVB phototherapy
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo plus narrowband UVB phototherapy
Number of subjects: 24
Study: 15262119

Group type: EXPERIMENTAL
Intervention: Intraperitoneal IL-2 therapy
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sera from nonresponders
Number of subjects: 17

Group type: COMPARATOR
Intervention: Chromatographically fractionated sera from nonresponders
Number of subjects: 17
Study: 11481400

Group type: EXPERIMENTAL
Intervention: Controlled low carotenoid diets
Number of subjects: 19
Study: 9544599

Group type: EXPERIMENTAL
Intervention: EDOU care
Number of subjects: 113

Group type: COMPARATOR
Intervention: Hospital Inpatient care
Number of subjects: 113
Study: 7511150

Group type: EXPERIMENTAL
Intervention: Aprotinin (Group A)
Number of subjects: 109
Study: 2899234

Group type: EXPERIMENTAL
Intervention: diazepam
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: dothiepin
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: cognitive and behaviour therapy
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: self‐help treatment programme
Number of subjects: 210

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 210
Study: 31631314

Group type: EXPERIMENTAL
Intervention: Cricoid force
Number of subjects: 74

Group type: COMPARATOR
Intervention: Paralaryngeal force
Number of subjects: 74
Study: 31356896

Group type: EXPERIMENTAL
Intervention: Neurofeedback intervention (EEG-contingent stimulation)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham-control (sensorimotor stimulations independent of EEG)
Number of subjects: 17
Study: 29128736

Group type: EXPERIMENTAL
Intervention: Autonomy-supportive practice conditions
Number of subjects: 40

Group type: COMPARATOR
Intervention: Autonomy-controlling practice conditions
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Increasing choice (1-2-3-4) sequence
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Overall motivation on the IMI
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Attention to the task on the UES Average Focused Attention subscale
Number of subjects: 40